Study Details

Open

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

The purpose of this study is to test the safety of a drug called CA-4948 in combination with gemcitabine and nab-paclitaxel. Gemcitabine and nab-paclitaxel have already been approved by the FDA to be given through a vein in your arm. This study tests different doses of the drug CA-4948 to see which dose is safer for people. There will be about 36 people taking part in this study.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

United States (Nationwide)

What will be asked of you

During the screening process, the patient will have a physical exam, vital signs collected, height and weight, labs collected, EKG, imaging scan, and biopsy. During study treatment, the patient will have a physical exams, vital signs collected, weight, labs collected, EKGs, imaging scans, biopsies, and receive study drug.

Incentives

In-person visits:
20 (depending on when the patient comes off treatment)

Phone or online visits:
4

Total length of participation:
18-24 months (depending on when the patient comes off treatment)

Looking for Specific Volunteers

Able to participate:

Patient has Pancreatic Cancer that has spread.
Patient recently had a scan that showed progression of their Pancreatic Cancer
Patient has no other prior or current cancer.
Patient has lesions that can be biopsied if enrolling in expansion cohort.

Not eligible if:

Patient had chemotherapy or radiotherapy within 4 weeks prior to entering the study.
Patient did not recover from clinically significant side effects from prior anti-cancer therapy.
Patient has a history of another Cancer.
Patient is using any alternative, holistic, naturopathic, or botanical meds for their Cancer treatment.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Trials Office
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Ashwin Somasundaram
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Pancreatic)

IRB Number

23-1040

ClinicalTrials.gov

NCT05685602